Author/Authors :
Ugan, Yunus Suleyman Demirel University - Faculty of Medicine - Department of Internal Medicine, Division of Rheumatology, Turkey , Sahin, Mehmet Suleyman Demirel University - Faculty of Medicine - Department of Internal Medicine, Division of Rheumatology, Turkey , Tunc, Sevket Ercan Suleyman Demirel University - Faculty of Medicine - Department of Internal Medicine, Division of Rheumatology, Turkey , Arici, Ozgur Suleyman Demirel University - Faculty of Medicine - Department of Internal Medicine, Turkey , Kapucuoglu, Nilgun Suleyman Demirel University - Faculty of Medicine - Department of Pathology, Turkey , Ermis, Fatih Isparta State Hospital - Department of Gastroenterology, Turkey
Abstract :
New targeted therapies have been noted after illumination of the pathogenesis of rheumatic diseases particularly in rheumatoid arthritis (RA), recently. These are usually cytokine-based therapies, tumor necrosis factor alpha (TNF-α) blocker is one of them. Etanercept which is a soluble TNF-a surface receptor has been reported to be associated with various solid organ tumors development.
